Lipids

Jul 27, 2017

Although statins have a proven benefit and are widely used, ASCVD continues to be the leading cause of death in the US.1-3  There is documented residual CV risk apparent even in patients treated with optimally-dosed statins.1,3 However, the 2013 ACC/AHA guidelines recommend against the routine use of statin add-on therapies.1 In 2015, two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab (Praluent®) and evolocumab (Repatha®), were ap

Comments: 2      Views: 2



Sep 15, 2016

Primary prevention is rooted at the foundation of public health by promoting interventions to decrease healthcare utilization and disease burden.

Comments: 1      Views: 1



Feb 28, 2016

With over 75% of people using mobile phones worldwide, text messaging might be a simple, cost-effective platform to encourage lifestyle changes.1  mHealth involves the use of mobile and wireless devices (e.g., wearable sensor technology) to provide health services and information.2,3  Such technologies have the potential to fundamentally change health practices.  Indeed, several healthcare-related applications and mobile phone text messaging systems have already been des

Comments: 0      Views: 0



Sep 5, 2015

Monoclonal antibodies (mAb) are used to treat many disorders — from cancer to age related macular degeneration.

Comments: 1      Views: 1



Jul 28, 2015

Clinical practitioners have used calculators such as the Framingham Risk Score to assess the probability that a patient will develop coronary heart disease (CHD) and to guide primary prevention therapy for decades.1  In 2013, the American College of Cardiology (ACC) and the American Heart Association (AHA) released an updated risk calculator which has been widely criticized and may lead to over-prescribing of cholesterol-lowering agents (namely statins), aspirin, and antihypertensi

Comments: 7      Views: 7



Feb 16, 2015

Current cholesterol guidelines promote the use of statins as first line therapy in primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) events. Despite the impressive risk reduction associated with statins, a 60% to 80% residual risk of vascular events remains. Does adding niacin to statin treatment reduce residual risk?  Or does statin therapy alone offer optimal benefit?

Comments: 2      Views: 2



Feb 5, 2014

In the United States, nearly 70% of adults are overweight or obese.1  Excess adipose tissue increases the likelihood of developing sleep apnea, type 2 diabetes mellitus (T2DM), dyslipidemia, and hypertension. The rate of all-cause mortality in obese individuals is higher when compared to normal weight individuals.2 Its imperative that we address body weight with all patients in all health care settings – but particularly in primary care settings.

Comments: 1      Views: 1



Dec 6, 2013

We’ve all encountered patients who’ve had difficulty taking their medications as prescribed.  Many of our patients don’t achieve the recommended treatment goals or derive much benefit their medications.  There are many reasons why patients don’t take their medications in an ideal manner — including cost barriers, unpleasant side effects, treatment complexity, and forgetfulness.  

Comments: 1      Views: 1



Sep 30, 2012

The biggest superstar in the dietary supplement industry is fish oil.  It is available over-the-counter and you can even buy orange juice fortified with it. Unfortunately, most of these products contain very low amounts of omega-3 fatty acids (O3FA).

Comments: 2      Views: 2



Feb 3, 2012

Yet another clinical trial attempting to prove that adding a second lipid lowering agent to a statin-based regimen has failed.

Comments: 1      Views: 1



Sep 29, 2011

The evidence regarding the benefits of statin therapy in patients with chronic kidney disease has been far from clear.

Comments: 1      Views: 1



Aug 8, 2011

In May 2011, the National Heart Lung and Blood Institute (NHLBI) announced the early termination of the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health (better known as the AIM-HIGH) trial due to lack of benefit from extended release niacin when add to simvastatin (+/- ezetimibe).  AIM-HIGH was a double-blind, randomized, placebo-controlled outcomes trial with over 3000 patien

Comments: 0      Views: 0



Aug 8, 2011

In May 2011, the National Heart Lung and Blood Institute (NHLBI) announced the early termination of the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health (better known as the AIM-HIGH) trial due to lack of benefit from extended release niacin when add to simvastatin (+/- ezetimibe).  AIM-HIGH was a double-blind, randomized, placebo-controlled outcomes trial with over 3000 patien

Comments: 0      Views: 0



Nov 5, 2010

The ARBITER-6 HALTS study examined the benefits of statin add-on therapy with either ezetimibe or niacin. Although not intended to be an outcome study, a significant difference between exetimibe and niacin in terms of cardiovascular events was observed in this study. How much weight should we give to this surprising finding?

Comments: 0      Views: 0